These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 815025)
21. Attempts to target antitumor drugs toward opioid receptor-rich mouse tumor cells with enkephalin-ellipticinium conjugates. Rigaudy P; Charcosset JY; Garbay-Jaureguiberry C; Jacquemin-Sablon A; Roques BP Cancer Res; 1989 Apr; 49(7):1836-42. PubMed ID: 2538235 [TBL] [Abstract][Full Text] [Related]
22. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)]. Rouesse J; Tursz T; Le Chevalier T; Huertas D; Amiel JL; Brule G; Callet B; Droz JP; Voisin PM; Sancho-Garnier H; Le Pecq JB; Paoletti C Nouv Presse Med; 1981 May; 10(24):1997-9. PubMed ID: 7255136 [TBL] [Abstract][Full Text] [Related]
23. Basically substituted ellipticine analogues as potential antitumor agents. Werbel LM; Angelo M; Fry DW; Worth DF J Med Chem; 1986 Jul; 29(7):1321-2. PubMed ID: 3806584 [TBL] [Abstract][Full Text] [Related]
24. Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2. Lempereur L; Sautereau AM; Tocanne JF; Laneelle G Biochem Pharmacol; 1984 Aug; 33(15):2499-503. PubMed ID: 6466364 [TBL] [Abstract][Full Text] [Related]
25. Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro. Samadi-Baboli M; Favre G; Blancy E; Soula G Eur J Cancer Clin Oncol; 1989 Feb; 25(2):233-41. PubMed ID: 2702978 [TBL] [Abstract][Full Text] [Related]
26. Dynamics of drug-DNA interactions: a comparative temperature jump study of ellipticinium and 9-hydroxy ellipticinium. Schwaller MA; Aubard J; Dodin G J Biomol Struct Dyn; 1988 Dec; 6(3):443-58. PubMed ID: 3271531 [TBL] [Abstract][Full Text] [Related]
27. Antitumoral activity of dipyrido [4,3-b] [3,4-f] indoles on L 1210 leukemia. Lidereau R; Chermann JC; Gruest J; Montagnier L; Ducrocq C; Rivalle C; Bisagni E Bull Cancer; 1980; 67(1):1-8. PubMed ID: 7362880 [TBL] [Abstract][Full Text] [Related]
28. Synthesis and antitumor activity of quaternary ellipticine glycosides, a series of novel and highly active antitumor agents. Honda T; Kato M; Inoue M; Shimamoto T; Shima K; Nakanishi T; Yoshida T; Noguchi T J Med Chem; 1988 Jul; 31(7):1295-305. PubMed ID: 3385725 [TBL] [Abstract][Full Text] [Related]
29. Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer. Delbarre A; Oberlin R; Roques BP; Borgna JL; Rochefort H; Le Pecq JB; Jacquemin-Sablon A J Med Chem; 1985 Jun; 28(6):752-61. PubMed ID: 4009597 [TBL] [Abstract][Full Text] [Related]
30. Influence of inducers of monooxygenases on cytotoxic efficiency of ellipticine on leukemia L1210 cells. Lesca P; Monsarrat B; Cros S; Paoletti C J Natl Cancer Inst; 1981 Oct; 67(4):871-6. PubMed ID: 6944554 [TBL] [Abstract][Full Text] [Related]
32. A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Le Pecq JB; Nguyen-Dat-Xuong ; Gosse C; Paoletti C Proc Natl Acad Sci U S A; 1974 Dec; 71(12):5078-82. PubMed ID: 4531039 [TBL] [Abstract][Full Text] [Related]
33. Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro. Dugue B; Paoletti C; Meunier B Biochem Biophys Res Commun; 1984 Oct; 124(2):416-22. PubMed ID: 6388575 [TBL] [Abstract][Full Text] [Related]
34. Syntheses and in vitro evaluation of water-soluble "cationic metalloporphyrin-ellipticine" molecules having a high affinity for DNA. Ding L; Etemad-Moghadam G; Cros S; Auclair C; Meunier B J Med Chem; 1991 Mar; 34(3):900-6. PubMed ID: 2002470 [TBL] [Abstract][Full Text] [Related]
35. Uptake and cytofluorescence localization of ellipticine derivatives in sensitive and resistant Chinese hamster lung cells. Charcosset JY; Salles B; Jacquemin-Sablon A Biochem Pharmacol; 1983 Mar; 32(6):1037-44. PubMed ID: 6838650 [TBL] [Abstract][Full Text] [Related]
36. Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule. Dodion P; Rozencweig M; Nicaise C; Piccart M; Cumps E; Crespeigne N; Kisner D; Kenis Y Eur J Cancer Clin Oncol; 1982 Jun; 18(6):519-22. PubMed ID: 6889528 [TBL] [Abstract][Full Text] [Related]
37. A new series of ellipticine derivatives (1-(alkylamino)-9-methoxyellipticine). Synthesis, DNA binding, and biological properties. Larue L; Rivalle C; Muzard G; Paoletti C; Bisagni E; Paoletti J J Med Chem; 1988 Oct; 31(10):1951-6. PubMed ID: 3172128 [TBL] [Abstract][Full Text] [Related]
38. [Anti-inflammatory effect of hydroxy-9-ellipticine]. Cros J; Thibault A; Dat-Xuong N C R Acad Hebd Seances Acad Sci D; 1975 Oct; 281(15):1139-42. PubMed ID: 813888 [TBL] [Abstract][Full Text] [Related]